Intellia Therapeutics announces first patient dosed in MAGNITUDE-2 trial

Intellia Therapeutics (NTLA) announced the first patient has been dosed in MAGNITUDE-2, a global, pivotal Phase 3 trial of nexiguran ziclumeran, nex-z, for the treatment of hereditary ATTR amyloidosis with polyneuropathy, ATTRv-PN. “We are pleased to have dosed the first patient with a treatment that has such strong potential to redefine the treatment paradigm for those living with ATTR with polyneuropathy. This is a debilitating, progressive disease that leaves people feeling increasingly helpless,” said Dr. Paulo Sgobbi, Medical Director, PSEG Clinical Research Center. “Through nex-z’s potential to favorably impact disease progression, patients living with ATTR polyneuropathy could experience life-changing benefit while being freed from the existing chronic treatment regimen of pills, injections and infusions.”